RudaCure Pursues Global Partnering for RCI001/RCI002 and Expanded Terapia Génica Co-Development at 2025 BIO-USA
RudaCure Inc. anunció its participación in the **BIO International Convention (BIO-USA)** 2025 celebrado en the United States, where it realizará overseas licensing and codesarrollo partnering meetings for its major pipelines: RCI001 (tratamiento de la enfermedad de ojo seco) and **RCI002 (TRPV1-targeted analgesic)**.
At the event, RudaCure will meet with world-renowned producto farmacéutico oftálmico empresas including Santen of Japan and Thea of France to share the desarrollo status and nacional/internacional ensayo clínico progreso of RCI001, and conduct in-depth discussions on codesarrollo and mercado global entry possibilities.
In the field of analgesic desarrollo, la empresa planea present the investigación resultados and commercial potential of RCI002 to major global empresas farmacéuticas. RCI002, a candidato a nuevo fármaco that simultaneously targets TRPV1 and MOR (Mu-Opioid Receptor), has demostró potent efectos analgésicos at very low doses in estudios preclínicos, earning attention as a analgésico no narcótico that overcomes the addiction and tolerance issues of opioid-based tratamientos. Various empresas have shown strong interest, and this BIO-USA provides an important opportunity to explore specific licenciamiento and codesarrollo models.
RudaCure actualmente está also pursuing codesarrollo of a terapia génica-based tratamiento del dolor for veterinario use, leveraging its proprietary dirigido a canales iónicos peptide tecnología combined with AAV (Adeno-Associated Virus) vectors. This proyecto, recently seleccionada for the Ministry of Agriculture's Agri-Food Venture Development Program, se espera que serve as a tecnología de plataforma applicable to both human and farmacéutico veterinarios, and discussions with multiple overseas partners are esperado to accelerate during BIO-USA.
El CEO Yongho Kim declaró: "BIO-USA 2025 will be a pivotal milestone for RudaCure's expansión global. Based on the clinical resultados of RCI001 and the innovador mechanism of RCI002, we will proactively advance asociacións with global empresas farmacéuticas and establish ourselves as a new drug developer with global presence."
